DAVENPORT & Co LLC Has $4.17 Million Holdings in Gilead Sciences, Inc. $GILD

DAVENPORT & Co LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,561 shares of the biopharmaceutical company’s stock after selling 6,026 shares during the period. DAVENPORT & Co LLC’s holdings in Gilead Sciences were worth $4,169,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Activest Wealth Management lifted its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $27,000. Putney Financial Group LLC boosted its holdings in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the period. Finally, Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the 2nd quarter valued at about $30,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $124.70 on Friday. The company has a market cap of $154.71 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 0.70 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock has a fifty day moving average price of $122.95 and a 200-day moving average price of $116.61.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Mizuho lifted their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. The Goldman Sachs Group upped their price objective on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Needham & Company LLC increased their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, TD Cowen boosted their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $131.54.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total value of $366,000.00. Following the transaction, the insider directly owned 106,221 shares of the company’s stock, valued at $12,958,962. This trade represents a 2.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 136,257 shares of company stock worth $16,723,492 in the last three months. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.